The stock of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) hit a new 52-week low and has $4.70 target or 14.00% below today’s $5.47 share price. The 9 months bearish chart indicates high risk for the $365.54M company. The 1-year low was reported on Oct, 17 by Barchart.com. If the $4.70 price target is reached, the company will be worth $51.18M less.
The 52-week low event is an important milestone for every stock because it shows very negative momentum and is time when sellers come in. During such technical setups, fundamental investors usually stay away and are careful buying the stock. About 43,898 shares traded hands. Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has declined 31.49% since March 14, 2016 and is downtrending. It has underperformed by 37.10% the S&P500.
Analysts await Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) to report earnings on November, 11. They expect $-0.23 earnings per share, down 1,050.00% or $0.21 from last year’s $-0.02 per share. After $-0.31 actual earnings per share reported by Adaptimmune Therapeutics PLC – ADR for the previous quarter, Wall Street now forecasts -25.81% EPS growth.
According to Zacks Investment Research, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.”
More important recent Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) news were published by: Marketwatch.com which released: “Adaptimmune Therapeutics PLC ADR” on April 14, 2015, also Quotes.Wsj.com published article titled: “DOW JONES, A NEWS CORP COMPANY”, Benzinga.com published: “Stocks Hitting 52-Week Lows” on October 12, 2016. More interesting news about Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) was released by: Equitiesfocus.com and their article: “Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Basic Consolidated EPS At $-0 …” with publication date: October 07, 2016.
ADAP Company Profile
Adaptimmune Therapeutics plc, incorporated on December 03, 2014, is a clinical-stage biopharmaceutical company. The Firm is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Firm has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Firm develops TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.